Each existing shareholder had received one right per share to subscribe for three new shares. The capital increase resulted in the issuance of 20,667,192 new ordinary shares with a nominal value of NIS 0.01 each, more than doubling the number of issued shares. Gross proceeds of approximately CHF 12.4 million have been generated. First trading day of the new shares on SIX Swiss Exchange in the International Reporting Standard is today. The capital increase will support SHL’s strategic turnaround, including investments in operational systems and expansion in the U.S. market.
Our Swiss team was proud to act as Transaction and Listing Counsel for this cross-border capital markets transaction. Drawing on deep experience in complex, multi-jurisdictional deals, our Capital Markets specialists guided SHL through every stage of the process, ensuring a smooth and successful outcome. By combining legal and tax expertise, we help clients navigate dynamic markets and achieve their strategic goals with confidence.
Disclaimer: This summary reflects the official public disclosure by SHL Telemedicine.
